Q32 Bio Inc. (QTTB )

Currency in USD Disclaimer
$3.41 -$0.21 (-5.8%)
Open 12/05/2025
$3.3
$3.66
$1.35
$28.06

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol QTTB
  • Company Q32 Bio Inc.
  • Price $3.41
  • Changes Percentage -5.8
  • Change -0.21
  • Day Low $3.3
  • Day High $3.66
  • Year High $28.06
  • Year Low $1.35
  • Market Cap $41,952,579
  • Price Avg 50 EMA (D) $2.64
  • Price Avg 200 EMA (D) $2.06
  • Exchange NASDAQ
  • Volume 375,643
  • Average Volume 3,037,195
  • Open $3.5
  • Previous Close $3.62
  • EPS -3.4
  • PE -1.00
  • Earnings Announcement 2026-03-10 04:00:00
  • Shares Outstanding $12,302,809

Company brief: Q32 BIO INC. (QTTB )

  • Healthcare
  • Biotechnology
  • Ms. Jodie Pope Morrison
  • N/A
  • 03-28-2018
  • US7469641051

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32’s complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

QTTB Corporation News

Income Statement